New Approaches to the Treatment of Dense Deposit Disease
- 1 September 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 18 (9), 2447-2456
- https://doi.org/10.1681/asn.2007030356
Abstract
The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.Keywords
This publication has 73 references indexed in Scilit:
- Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient miceProceedings of the National Academy of Sciences of the United States of America, 2006
- Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndromeThe EMBO Journal, 2006
- Drugs for exceptionally rare diseases: do they deserve special status for funding?QJM: An International Journal of Medicine, 2005
- Recurrence of Membranoproliferative Glomerulonephritis Type II in Renal AllograftsJournal of the American Society of Nephrology, 2005
- A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann NephritisJournal of the American Society of Nephrology, 2004
- Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II (“dense deposit disease”)American Journal of Kidney Diseases, 2003
- Management of membranoproliferative glomerulonephritis type II with plasmapheresisJournal of Clinical Apheresis, 2002
- Molecular analysis of C3 allotypes in patients with nephritic factorClinical and Experimental Immunology, 1993
- Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report.British Journal of Ophthalmology, 1989
- Genetically determined variation in the complement system: Relationship to diseaseThe Journal of Pediatrics, 1984